Weight Management with Orlistat in Type 2 Diabetes - An Electronic Healthcare Records Study
CONCLUSIONS: Orlistat was significantly associated with weight loss in T2DM/prediabetes when taken for at least 12 weeks. However, orlistat is infrequently prescribed and often taken for <12 weeks. Orlistat may be a useful adjunct to lifestyle modifications in T2DM/prediabetes however barriers to continuing orlistat means it may not be effective for everyone in managing weight loss.PMID:38621802 | DOI:10.3399/BJGP.2023.0684
Source: The British Journal of General Practice - Category: Primary Care Authors: Shraboni Ghosal Neil Heron Kayleigh Mason James Bailey Kelvin Jordan Source Type: research
More News: Alli | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Diets | Endocrinology | Fortamet | General Practices | Hypertension | Jordan Health | Metformin | Middle East Health | Nutrition | Primary Care | Smokers | Sports Medicine | Study | UK Health | Weight Loss | Xenical